{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:00:54Z","timestamp":1780592454728,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"DOI":"10.7759\/cureus.110247","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:00:42Z","timestamp":1780588842000},"source":"Crossref","is-referenced-by-count":0,"title":["Discharge Prescription of Renin-Angiotensin System Inhibitors After Hyperkalemia and Its Association With Mortality and Dialysis Outcomes"],"prefix":"10.7759","author":[{"given":"Yarden","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Cohen-Yatziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Ben Shimol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimrod","family":"Adatto Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Beberashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Efrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Zilberman Itskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh TA","year":"2024","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2024, 26:5-17. 10.1002\/ejhf.3024","journal-title":"Eur J Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy JW","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al.. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024, 45:3912-4018. 10.1093\/eurheartj\/ehae178","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin A","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, et al.. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024, 105:684-701. 10.1016\/j.kint.2023.10.016","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022, 45:3075-90. 10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/17511437241230260","article-title":"Association between critical care admission and chronic medication discontinuation post-hospital discharge: a retrospective cohort study","volume":"25","author":"Kanodia C","year":"2024","unstructured":"Kanodia C, Bourne RS, Mansi ET, Lone NI. Association between critical care admission and chronic medication discontinuation post-hospital discharge: a retrospective cohort study. J Intensive Care Soc. 2024, 25:255-65. 10.1177\/17511437241230260","journal-title":"J Intensive Care Soc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter RW","year":"2019","unstructured":"Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019, 34:iii2-iii11. 10.1093\/ndt\/gfz206","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel MA","year":"2012","unstructured":"Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012, 30:e156-66. 10.1111\/j.1755-5922.2010.00258.x","journal-title":"Cardiovasc Ther"},{"key":"ref8","unstructured":"Clinical practice guidelines treatment of acute hyperkalemia in adults. (2026). https.\/\/www.ukkidney.org\/sites\/default\/files\/RENAL%20ASSOCIATION%20HYPERKALAEMIA%20GUIDELINE%20-%20JULY%202022%20V2_0...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano GM","year":"2018","unstructured":"Rosano GM, Tamargo J, Kjeldsen KP, et al.. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018, 4:180-8. 10.1093\/ehjcvp\/pvy015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref10","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein M","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015, 21:S212-20.","journal-title":"Am J Manag Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon SJ","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, et al.. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022, 80:164-173. 10.1053\/j.ajkd.2022.01.002","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao Y","year":"2020","unstructured":"Qiao Y, Shin JI, Chen TK, et al.. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020, 180:718-26. 10.1001\/jamainternmed.2020.0193","journal-title":"JAMA Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.10.016","article-title":"New strategies for the treatment of hyperkalemia","volume":"132","author":"Masi S","year":"2025","unstructured":"Masi S, Dalpiaz H, Piludu S, Piani F, Fiorini G, Borghi C. New strategies for the treatment of hyperkalemia. Eur J Intern Med. 2025, 132:18-26. 10.1016\/j.ejim.2024.10.016","journal-title":"Eur J Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02198-6","article-title":"Novel potassium binders in reduction of hyperkalemia and optimization of raas inhibitors treatment in patients with chronic kidney disease or heart failure: a systematic review and meta-analysis","volume":"85","author":"Huang N","year":"2025","unstructured":"Huang N, Xu Y, Liu C, et al.. Novel potassium binders in reduction of hyperkalemia and optimization of raas inhibitors treatment in patients with chronic kidney disease or heart failure: a systematic review and meta-analysis. Drugs. 2025, 85:1013-31. 10.1007\/s40265-025-02198-6","journal-title":"Drugs"},{"key":"ref15","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000, 355:253-9.","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf S","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302. 10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.07.010","article-title":"Hyperkalemia and treatment with RAAS\u00a0inhibitors during acute heart\u00a0failure hospitalizations and their\u00a0association with mortality","volume":"7","author":"Beusekamp JC","year":"2019","unstructured":"Beusekamp JC, Tromp J, Cleland JG, et al.. Hyperkalemia and treatment with RAAS\u00a0inhibitors during acute heart\u00a0failure hospitalizations and their\u00a0association with mortality. JACC Heart Fail. 2019, 7:970-9. 10.1016\/j.jchf.2019.07.010","journal-title":"JACC Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf343","article-title":"Urgent initiation of hemodialysis versus peritoneal dialysis in severe hyperkalemia: a prospective study","volume":"18","author":"Alcantar-Vallin L","year":"2025","unstructured":"Alcantar-Vallin L, Zaragoza JJ, Ru\u00edz-Ochoa FO, et al.. Urgent initiation of hemodialysis versus peritoneal dialysis in severe hyperkalemia: a prospective study. Clin Kidney J. 2025, 18:sfaf343. 10.1093\/ckj\/sfaf343","journal-title":"Clin Kidney J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100879","article-title":"Hyperkalemia incidence in patients with non-dialysis chronic kidney disease: a large retrospective cohort study from United States Clinical Care","volume":"6","author":"van Boemmel-Wegmann S","year":"2024","unstructured":"van Boemmel-Wegmann S, Bauer C, Schuchhardt J, et al.. Hyperkalemia incidence in patients with non-dialysis chronic kidney disease: a large retrospective cohort study from United States Clinical Care. Kidney Med. 2024, 6:100879. 10.1016\/j.xkme.2024.100879","journal-title":"Kidney Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S326464","article-title":"Hyperkalemia in chronic kidney disease: links, risks and management","volume":"15","author":"Sarnowski A","year":"2022","unstructured":"Sarnowski A, Gama RM, Dawson A, Mason H, Banerjee D. Hyperkalemia in chronic kidney disease: links, risks and management. Int J Nephrol Renovasc Dis. 2022, 15:215-28. 10.2147\/IJNRD.S326464","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer BF","year":"2021","unstructured":"Palmer BF, Carrero JJ, Clegg DJ, et al.. Clinical management of hyperkalemia. Mayo Clin Proc. 2021, 96:744-62. 10.1016\/j.mayocp.2020.06.014","journal-title":"Mayo Clin Proc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2021.100635","article-title":"Patiromer and Sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis","volume":"95","author":"Shrestha DB","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, et al.. Patiromer and Sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2021, 95:100635. 10.1016\/j.curtheres.2021.100635","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1774363","article-title":"Patiromer for the treatment of hyperkalemia","volume":"13","author":"Colbert GB","year":"2020","unstructured":"Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020, 13:563-70. 10.1080\/17512433.2020.1774363","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham DK","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, et al.. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015, 372:222-31. 10.1056\/NEJMoa1411487","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae056","article-title":"Hyperkalemia treatment standard","volume":"39","author":"Palmer BF","year":"2024","unstructured":"Palmer BF, Clegg DJ. Hyperkalemia treatment standard. Nephrol Dial Transplant. 2024, 39:1097-104. 10.1093\/ndt\/gfae056","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03427-0","article-title":"Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors","volume":"19","author":"De Nicola L","year":"2024","unstructured":"De Nicola L, Ferraro PM, Montagnani A, Pontremoli R, Dentali F, Sesti G. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors. Intern Emerg Med. 2024, 19:295-306. 10.1007\/s11739-023-03427-0","journal-title":"Intern Emerg Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.210831","article-title":"Prevention and management of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors","volume":"193","author":"Weinstein J","year":"2021","unstructured":"Weinstein J, Girard LP, Lepage S, McKelvie RS, Tennankore K. Prevention and management of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. CMAJ. 2021, 193:E1836-41. 10.1503\/cmaj.210831","journal-title":"CMAJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492142-discharge-prescription-of-renin-angiotensin-system-inhibitors-after-hyperkalemia-and-its-association-with-mortality-and-dialysis-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:00:45Z","timestamp":1780588845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492142-discharge-prescription-of-renin-angiotensin-system-inhibitors-after-hyperkalemia-and-its-association-with-mortality-and-dialysis-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.110247","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}